TCD601 for Type-1 Diabetes
Type-1 Diabetes (New-onset remission)
Phase 2Active
Key Facts
About ITB Med
ITB-MED is a clinical-stage biotech pioneering a transformative approach to organ transplantation and autoimmunity. Its central mission is to induce immune tolerance, freeing patients from lifelong immunosuppression, which could dramatically improve health outcomes, quality of life, and reduce long-term healthcare costs. The company's pipeline is built around its proprietary CD2 antagonist, TCD601, with multiple programs in transplantation and autoimmunity, several of which have advanced into clinical development. With a seasoned leadership team and operations spanning two continents, ITB-MED is positioning itself as a key player in the next generation of immunomodulatory therapies.
View full company profile